Drug Screening Market Segmentation:
Product Type Segment Analysis
The rapid testing devices segment is projected to account for 30% share of the drug screening market by 2035. The segment's rise is attributable to the increasing demand for onsite testing across various industries, including healthcare, sports, and government agencies. Rapid testing devices provide a quick and easy way to screen individuals for drugs, making them an attractive option for these industries. In addition, these devices are undergoing significant technological advancements, resulting in improved convenience and sensitivity. On this note, in May 2024, eMed launched a fully remote proctored drug screening solution, eMed Screen, to provide instant results for employers. These factors are conjugately making these devices a more reliable and effective option for customers, rising adoption in this segment.
End user Segment Analysis
The hospital segment is predicted to hold approximately 35% share of the drug screening market over the assessed timeline. The presence of a high number of patients in these organizations, which is rapidly expanding, is fueling the segment's expansion. The availability of a wide range of healthcare professionals, such as physicians and doctors, who are specialized in internal medicine, pediatrics, or general practice is also a major driver in this segment’s growth. In addition, the sufficient supply of required resources to solve unique problems is magnifying the priority of hospitals as a first point-of-care for patients. Moreover, the increased public expenditure on these service providers for SUD treatment is contributing to this segment’s leadership.
Our in-depth analysis of the global drug screening market includes the following segments:
|
|
|
|
Product Type |
|
